BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21995575)

  • 1. Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer.
    Görgün G; Anderson KC
    Immunotherapy; 2011 Oct; 3(10):1253-64. PubMed ID: 21995575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the stroma by T cells to limit tumor growth.
    Zhang B
    Cancer Res; 2008 Dec; 68(23):9570-3. PubMed ID: 19047130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy: target the stroma to hit the tumor.
    Kammertoens T; Schüler T; Blankenstein T
    Trends Mol Med; 2005 May; 11(5):225-31. PubMed ID: 15882610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-stroma interactions directing phenotype and progression of epithelial skin tumor cells.
    Mueller MM; Fusenig NE
    Differentiation; 2002 Dec; 70(9-10):486-97. PubMed ID: 12492491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting stromal-cancer cell interactions with siRNAs.
    Aharinejad S; Sioud M; Lucas T; Abraham D
    Methods Mol Biol; 2009; 487():243-66. PubMed ID: 19301651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular therapy to control tumor progression.
    Kapp M; Rasche L; Einsele H; Grigoleit GU
    Curr Opin Hematol; 2009 Nov; 16(6):437-43. PubMed ID: 19587587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
    Puré E; Lo A
    Cancer Immunol Res; 2016 Apr; 4(4):269-78. PubMed ID: 27036971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-host interactions: a far-reaching relationship.
    McAllister SS; Weinberg RA
    J Clin Oncol; 2010 Sep; 28(26):4022-8. PubMed ID: 20644094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoid stroma in the initiation and control of immune responses.
    Mueller SN; Ahmed R
    Immunol Rev; 2008 Aug; 224():284-94. PubMed ID: 18759934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting.
    Sung SY; Chung LW
    Differentiation; 2002 Dec; 70(9-10):506-21. PubMed ID: 12492493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immune response and cancer].
    El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
    Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of stroma in immune recognition and destruction of well-established solid tumors.
    Yu P; Rowley DA; Fu YX; Schreiber H
    Curr Opin Immunol; 2006 Apr; 18(2):226-31. PubMed ID: 16459066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple roles for CD4+ T cells in anti-tumor immune responses.
    Kennedy R; Celis E
    Immunol Rev; 2008 Apr; 222():129-44. PubMed ID: 18363998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive up-regulation of integrin-mediated adhesion of tumor-infiltrating lymphocytes to osteoblasts and bone marrow-derived stromal cells.
    Tanaka Y; Mine S; Hanagiri T; Hiraga T; Morimoto I; Figdor CG; van Kooyk Y; Ozawa H; Nakamura T; Yasumoto K; Eto S
    Cancer Res; 1998 Sep; 58(18):4138-45. PubMed ID: 9751626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-β, and extracellular matrix down-regulation.
    Coulson-Thomas VJ; Gesteira TF; Coulson-Thomas YM; Vicente CM; Tersariol IL; Nader HB; Toma L
    Exp Cell Res; 2010 Nov; 316(19):3207-26. PubMed ID: 20727350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From cancer immunosurveillance to cancer immunotherapy.
    Stagg J; Johnstone RW; Smyth MJ
    Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance.
    Cohen PA; Peng L; Kjaergaard J; Plautz GE; Finke JH; Koski GK; Czerniecki BJ; Shu S
    Crit Rev Immunol; 2001; 21(1-3):215-48. PubMed ID: 11642606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer.
    Katou F; Ohtani H; Watanabe Y; Nakayama T; Yoshie O; Hashimoto K
    Cancer Res; 2007 Dec; 67(23):11195-201. PubMed ID: 18056444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.